Cell ther­a­py pi­o­neer Mark Frohlich takes the helm at tiny In­dap­ta as a suite of big-name back­ers jump aboard

Off-the-shelf cell ther­a­py has be­come a red-hot field of in­vest­ment in re­cent years as the first rounds of hu­man da­ta start rolling out. Now, cell ther­a­py start­up In­dap­ta Ther­a­peu­tics is bring­ing in the big guns to dri­ve its pipeline for­ward — in­clud­ing one of the field’s most es­teemed names.

San Fran­cis­co-based In­dap­ta has ap­point­ed Mark Frohlich, who pre­vi­ous­ly ran port­fo­lio strat­e­gy at Juno and be­fore that the clin­ic shop at Den­dreon, as its newest CEO, re­plac­ing found­ing helms­man Guy DiP­ier­ro, who will step in­to the role of chief strat­e­gy of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER